These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9148359)

  • 21. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 22. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review.
    Duhl AJ
    J Reprod Med; 2008 Sep; 53(9):657-66. PubMed ID: 18839817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 26. Venous thromboembolism. A review.
    Thorneycroft IH; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):911-20. PubMed ID: 14686028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and management of venous thromboembolism in pregnancy.
    James AH
    Am J Med; 2007 Oct; 120(10 Suppl 2):S26-34. PubMed ID: 17916457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of postoperative venous thromboembolic complications].
    Savel'ev VS; Gologorskiĭ VA; Kirienko AI; Gel'fand BR
    Anesteziol Reanimatol; 2000; (4):68-71. PubMed ID: 11014003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of low-molecular-weight heparins in pregnancy--how safe are they?
    Deruelle P; Coulon C
    Curr Opin Obstet Gynecol; 2007 Dec; 19(6):573-7. PubMed ID: 18007136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-molecular-weight heparins: do we have the GUSTO to identify differences between alternative formulations?
    Zakarija A; Bennett CL
    Arch Intern Med; 2005 Apr; 165(7):722-3. PubMed ID: 15824289
    [No Abstract]   [Full Text] [Related]  

  • 34. Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines.
    Samama CM; Albaladejo P; Benhamou D; Bertin-Maghit M; Bruder N; Doublet JD; Laversin S; Leclerc S; Marret E; Mismetti P; Samain E; Steib A;
    Eur J Anaesthesiol; 2006 Feb; 23(2):95-116. PubMed ID: 16438749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venous thromboembolic disease and pregnancy.
    Marik PE; Plante LA
    N Engl J Med; 2008 Nov; 359(19):2025-33. PubMed ID: 18987370
    [No Abstract]   [Full Text] [Related]  

  • 36. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
    Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
    Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
    Del Bono R; Martini G; Volpi R
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):950-9. PubMed ID: 21845806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N; Arnaout L; Chabbouh T; Bellamy L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.